Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 15/20 | 0.60 |
| ▸ | NSD3 | Q9BZ95 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | NSD2 | O96028 | 1/20 | 0.49 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.48 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.48 |
| ▸ | PNP | P00491 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19945293 | 0.88 | TLR7 (0.59) | TLR7NSD3NSD2TLR8NUDT1 | |
| SCHEMBL19945683 | 0.87 | TLR7 (0.55) | TLR7NSD3NSD2TLR8NUDT1 | |
| SCHEMBL18207604 | 0.81 | TLR7 (0.68) | TLR7TLR8NUDT1 | |
| SCHEMBL29488791 | 0.81 | TLR7 (0.68) | TLR7TLR8NUDT1 | |
| SCHEMBL21287858 | 0.77 | TLR7 (0.67) | TLR7TLR8 | |
| SCHEMBL14429607 | 0.77 | ADORA2A (0.44) | TLR7ALDH1A1PNP | |
| SCHEMBL18207424 | 0.76 | TLR7 (0.65) | TLR7TLR8 | |
| SCHEMBL19969292 | 0.76 | TLR7 (0.82) | TLR7TLR8 | |
| SCHEMBL29488795 | 0.76 | TLR7 (0.65) | TLR7TLR8 | |
| SCHEMBL19945796 | 0.75 | TLR7 (1.00) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3970750-A1 | COMBINED TREATMENT WITH A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR | F. Hoffmann-La Roche AG (CH) | 2022-03-23 | — | — | EP | disclosed |
| EP-3865482-A1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2021-08-18 | — | — | EP | disclosed |
| EP-3512556-B1 | COMBINED TREATMENT WITH A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR | HOFFMANN LA ROCHE (CH) | 2021-08-18 | — | — | EP | disclosed |
| EP-3504210-B1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2021-02-24 | — | — | EP | disclosed |
| WO-2018050571-A1 | COMBINED TREATMENT WITH A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR | F. HOFFMANN-LA ROCHE AG (CH) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018041763-A1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2018-03-08 | — | — | WO | disclosed |